Eli Lilly and Company (NYSE:LLY) Shares Acquired by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 57.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 365,582 shares of the company’s stock after buying an additional 133,475 shares during the quarter. Eli Lilly and Company comprises 0.7% of Thrivent Financial for Lutherans’ holdings, making the stock its 12th biggest position. Thrivent Financial for Lutherans’ holdings in Eli Lilly and Company were worth $330,992,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. AMJ Financial Wealth Management purchased a new stake in Eli Lilly and Company in the 4th quarter worth approximately $201,000. Aveo Capital Partners LLC raised its holdings in Eli Lilly and Company by 8.2% during the fourth quarter. Aveo Capital Partners LLC now owns 2,020 shares of the company’s stock valued at $1,178,000 after buying an additional 153 shares in the last quarter. Gryphon Financial Partners LLC lifted its position in shares of Eli Lilly and Company by 19.4% in the fourth quarter. Gryphon Financial Partners LLC now owns 2,324 shares of the company’s stock worth $1,355,000 after buying an additional 377 shares during the last quarter. Quest Partners LLC bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $313,000. Finally, GW&K Investment Management LLC increased its holdings in shares of Eli Lilly and Company by 2.4% during the 4th quarter. GW&K Investment Management LLC now owns 754 shares of the company’s stock valued at $440,000 after acquiring an additional 18 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the completion of the sale, the insider now directly owns 96,943,810 shares in the company, valued at approximately $91,109,731,514.20. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 442,229 shares of company stock worth $410,002,456 over the last three months. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $921.72 on Friday. Eli Lilly and Company has a twelve month low of $516.57 and a twelve month high of $972.53. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The stock’s 50-day simple moving average is $895.06 and its 200 day simple moving average is $837.89. The firm has a market capitalization of $876.01 billion, a PE ratio of 135.75, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The company had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. On average, analysts anticipate that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.56%. The ex-dividend date was Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Wall Street Analyst Weigh In

LLY has been the subject of a number of recent analyst reports. Evercore ISI raised Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Berenberg Bank lifted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Guggenheim boosted their target price on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Citigroup assumed coverage on Eli Lilly and Company in a research report on Friday, September 13th. They set a “buy” rating and a $1,060.00 price objective for the company. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $1,106.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $977.35.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.